 Immutep Limited NASDAQ: IMMP has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncologys 2021 Annual Meeting. Data from Phase I INSIGHT trial evaluating eftilagimod alpha combined with Pfizer Incs NYSE: PFE Bavencio avelumab in advanced solid tumors showed: Five patients showed partial response PR as the best response, one stable disease with clinical progression all but one of these patients are still alive. 